Boston ScientificBSXEarnings & Financial Report
Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Revenue
$3.2B
Gross Profit
$2.2B
Operating Profit
$402.0M
Net Profit
N/A
Gross Margin
68.8%
Operating Margin
12.4%
Net Margin
N/A
YoY Growth
3.7%
EPS
$0.09
Financial Flow
Boston Scientific Q4 2022 Financial Summary
Boston Scientific reported revenue of $3.2B for Q4 2022, with a net profit of N/A (N/A margin). Cost of goods sold was $1.0B, operating expenses totaled $1.8B.
Key Financial Metrics
| Total Revenue | $3.2B |
|---|---|
| Net Profit | N/A |
| Gross Margin | 68.8% |
| Operating Margin | 12.4% |
| Report Period | Q4 2022 |
Boston Scientific Annual Revenue by Year
Boston Scientific annual revenue history includes year-by-year totals (for example, 2025 revenue was $20.1B).
| Year | Annual Revenue |
|---|---|
| 2025 | $20.1B |
| 2024 | $16.7B |
| 2023 | $14.2B |
| 2022 | $12.7B |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.86B | $4.12B | $4.21B | $4.56B | $4.66B | $5.06B | $5.07B | $5.29B |
| YoY Growth | 13.8% | 14.5% | 19.3% | 22.5% | 20.9% | 22.8% | 20.3% | 15.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $36.67B | $37.11B | $38.08B | $39.40B | $40.14B | $41.56B | $42.71B | $43.67B |
| Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | $19.93B | $20.37B | $20.71B | $21.77B | $22.21B | $22.42B | $23.39B | $24.23B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $164.0M | $813.0M | $1.00B | $1.46B | $541.0M | $1.29B | $1.34B | $1.36B |
Other Health Care Companies
ABT
Abbott Laboratories
Revenue
$11.4B
Net Profit
$1.6B
BAX
Baxter International
Revenue
$3.0B
Net Profit
$-1.1B
BDX
Becton Dickinson
Revenue
$5.3B
Net Profit
$382.0M
DXCM
Dexcom
Revenue
$1.3B
Net Profit
$267.3M
EW
Edwards Lifesciences
Revenue
$1.6B
Net Profit
$291.1M
GEHC
GE HealthCare
Revenue
$5.7B
Net Profit
$588.0M
HOLX
Hologic
Revenue
$1.0B
Net Profit
$179.1M
IDXX
Idexx Laboratories
Revenue
$1.1B
Net Profit
$274.6M
PODD
Insulet Corporation
Revenue
$783.7M
Net Profit
$101.6M
ISRG
Intuitive Surgical
Revenue
$2.9B
Net Profit
$794.8M